Pharma Stock Falls For 5th Straight Session, Declared Rs 70/Share Dividend In Last 12-Months

Large cap pharmaceuticals sector stock, Pfizer Ltd shares witnessed a decline for the fifth straight session today. Pfizer shares fell 1.46% in last 1-week, gained 0.11% in last 2-weeks, and declined again by 3.27% in last 1-month. Pfizer announced Rs 40/share dividend on May 15, 2023 for the financial year ended March 31, 2023 with record date fixed as August 11, 2023. Check details below:

Pfizer Dividend: The Board of Directors at its Meeting held on May 15, 2023, recommended a final dividend of 35/- (350%) per equity share and a special dividend of 5/- (50%) per equity share in view of the gain on account of the sale of business undertaking at Thane, aggregating to total dividend of 40/- (400%) for the financial year ended March 31, 2023, The payout for the said dividend will be 182.99 Crores." The said dividend if approved by the Members at the AGM, would be paid on or before September 16, 2023.
The company announced a special dividend of Rs 30/share last year with ex-dividend date set as September 19, 2022 and record date fixed as September 20, 2023.

The company so far declared 29 dividends since March 23, 2001 and offers a dividend yield of 1.82%

Pfizer Stock Performance & Return: Current market price of Pfizer share is Rs 3845.65 apiece with marginal intraday gain of 0.09%. The stock opened trading at Rs 3876.95, touched day's low of Rs 3835.80 apiece, and day's high of Rs 3882.65 apiece, respectively. Its 52-week high price is Rs 4662.35 apiece and 52-week low price is Rs 3406.95 apiece, respectively. The large cap company has a market capitalisation of Rs 17,567.36 crore. Pfizer stock fell 13% YTD, declined again by 32% in last 2-years, and gained 5% in last 5-years.

Pfizer Financials: The company for the quarter ended June 30, 2023 declared its standalone total income at Rs 564.82 crore, down 6.49% as against its last quarter total income of Rs 604.02 crore. It has announced its recent quarter net profit after tax at Rs 93.53 crore.

About: It has a leading portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas. It has an industry-leading pipeline of promising new products that have the potential to challenge some of the most feared diseases like Alzheimer's disease and cancer. The large cap pharmaceuticals sector company was incorporated in 1950.

Disclaimer

The stock just highlights the dividend, stock performance and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither, the author nor Greynium Information Technologies should be held liable for ay losses. Please consult a professional advisor.